668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.